Form 4: ARS Pharmaceuticals CEO Richard Lowenthal Sells Shares Under 10b5-1 Trading Plan

Richard Lowenthal, CEO of ARS Pharmaceuticals, sold shares of common stock on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Richard E Lowenthal, the President and CEO of ARS Pharmaceuticals, sold shares of the company's common stock on October 15, 2024.
• The sales were executed under a Rule 10b5-1 trading plan established on March 31, 2023.
• He sold 48,550 shares at a weighted average price of $14.8642, 1,450 shares at a weighted average price of $15.2539, and 50,000 shares at a weighted average price of $14.8764.
• Following these transactions, Lowenthal directly owns 4,315,313 shares.
• He also has indirect ownership through various trusts, including the Sarina Tanimoto Charitable Remainder UniTrust, the Lowenthal-Tanimoto Family Trust, and the Richard Lowenthal Charitable Remainder UniTrust, as well as shares held by his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially leading to short-term price fluctuations.

Industry Context

Insider sales are a common occurrence in publicly traded companies. Rule 10b5-1 plans allow insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.

Stakeholder Impact

• Shareholders may react to the news of insider selling, although the existence of a 10b5-1 plan can mitigate concerns.

Key Dates